Last reviewed · How we verify
Pain killer
At a glance
| Generic name | Pain killer |
|---|---|
| Sponsor | Azienda Ospedaliero-Universitaria di Modena |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Use of the Methoxyflurane as Pain-killer in the Prehospital Management of Acute Myocardial Infarction (PHASE3)
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
- Can Multimodal Medical Strategies Can Delay Total Knee Replacement? (NA)
- Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines (PHASE2)
- NK-ORB Expression of Mu Receptor on Lymphocytes in Rehabilitation
- Efficacy of Trypsin-Chymotrypsin On Post-operative Pain After Single Visit Root Canal Treatment (PHASE4)
- Effects of Anesthetic Technique on NK Cells (NA)
- Pain Killer, Anxiety and Mucogingival Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pain killer CI brief — competitive landscape report
- Pain killer updates RSS · CI watch RSS
- Azienda Ospedaliero-Universitaria di Modena portfolio CI